Over the years, Serbia has become a highly reputable place to conduct clinical research. The country has actively strived towards developing a robust healthcare system and has adopted a full GCP compliance. An increasing number of biotechnology and pharmaceutical companies are now willing to envision Serbia as a potential regional hub for their business operations and thus make significant investments in the Serbian market.
GTC 19 Avenue 38-40 Vladimira Popovica Street, Belgrade 11070, Serbia